Atlas Trials

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

Clinical trial NCT05896748 · COMPLETED

Trial details

NCT number
NCT05896748
Sponsor
ViiV Healthcare
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Human Immunodeficiency Virus Type 1 (HIV-1)
Start date
2022-11-08
Primary completion
2023-09-14
Enrollment
94

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.